Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 14, 2027; 33(2): 123795
Published online Jan 14, 2027. doi: 10.3748/wjg.123795
Published online Jan 14, 2027. doi: 10.3748/wjg.123795
Figure 5 Melatonin and AZD2171 inhibited angiogenesis in vitro.
A: Western blotting of VEGFR-2 and its phosphorylated form in human umbilical vein endothelial cells (HUVECs) treated with VEGFA, melatonin (MLT), or AZD2171; B: Quantitative analysis of VEGFR-2 phosphorylation; C: The proliferation assay of HUVECs treated with VEGFA, MLT, or AZD2171; D: The tube formation assay of HUVECs treated with VEGFA, MLT, or AZD2171; E: Quantitative analysis of tube formation assay; F: The wound healing assay of HUVECs treated with VEGFA, MLT, or AZD2171; G: Quantitative analysis of wound healing assay; H: Transwell migration assay of HUVECs treated with VEGFA, MLT, or AZD2171; I: Quantitative analysis of Transwell migration assay. aP < 0.05. bP < 0.01. MLT: Melatonin.
- Citation: Wu GB, Luo GQ, Chen M, Cai KW, You XT, Han F, Zhang NZ, Luo M, Li Q, Huo HZ, Fan Q. Melatonin attenuates splanchnic hyperdynamic circulation in cirrhotic portal hypertension by disrupting POMK-VEGFR2 interaction. World J Gastroenterol 2027; 33(2): 123795
- URL: https://www.wjgnet.com/1007-9327/full/v33/i2/123795.htm
- DOI: https://dx.doi.org/10.3748/wjg.123795